Larry Anderson, MD, PhD

home / authors / larry-anderson-md-phd

Articles

Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML

Larry Anderson, MD, PhD;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

July 28th 2023

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

Chronic-Phase CML: The OPTIC Study

Larry Anderson, MD, PhD;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

July 21st 2023

Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.

Relapsed/Refractory Multiple Myeloma: The KarMMa-3 Study

Larry Anderson, MD, PhD;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

July 21st 2023

Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic

Larry Anderson, MD, PhD;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

July 21st 2023

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.

Team Introductions: MM Experts From UT Southwestern vs Mayo Clinic

Larry Anderson, MD, PhD;Adeel Khan, MD, MPH, MS;Prashant Kapoor, MD;Wilson Gonsalves, MD;Abhishek Mangaonkar, MBBS;Kebede Begna, MD

July 21st 2023

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.

Transplant-Ineligible MM: Navigating Treatment Challenges

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 15th 2021

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Counseling Patients With MM About Treatment Duration

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 13th 2021

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Transplant-Ineligible MM: Reinitiating Therapy

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 8th 2021

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

Transplant-Ineligible MM: Treating to Progression

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 6th 2021

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

Maintenance Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 1st 2021

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

Triplet Vs Doublet Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 29th 2021

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Managing Adequate/Inadequate Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

MRD Testing in Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Frequency of Measuring Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 15th 2021

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW

Larry Anderson, MD, PhD

September 10th 2021

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.

Strategies to Monitor Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 10th 2021

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Goals of Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 8th 2021

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

Larry Anderson, MD, PhD, Discussed Updated Results of the KarMMa Trial at ASCO

Larry Anderson, MD, PhD

June 6th 2021

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.

<1 2